"Feb. 8, 2013 -- With winter cold and flu season in full swing -- and a new strain of norovirus circulating -- everyone's trying to dodge the bugs. Norovirus causes intestinal illness, and it's often the root of outbreaks at schools and in nursing"...
No overdosage with VIRAZOLE (ribavirin) by aerosol administration has been reported in humans. The LDM in mice is 2 g orally and is associated with hypoactivity and gastrointestinal symptoms (estimated human equivalent dose of 0.17 g/kg, based on body surface area conversion). The mean plasma half-life after administration of aerosolized VIRAZOLE (ribavirin) for pediatric patients is 9.5 hours. VIRAZOLE (ribavirin) is concentrated and persists in red blood cells for the life of the erythrocyte (see Pharmacokinetics).
VIRAZOLE (ribavirin) is contraindicated in individuals who have shown Hypersensitivity to the drug or its components, and in women who are or may become pregnant during exposure to the drug. Ribavirin has demonstrated significant teratogenic and/or embryocidal potential in all animal species in which adequate studies have been conducted (rodents and rabbits). Therefore, although clinical studies have not been performed, it should be assumed that VIRAZOLE (ribavirin) may cause fetal harm in humans. Studies in which the drug has been administered systemically demonstrate that ribavirin is concentrated in the red blood cells and persists for the life of the erythrocyte.
Last reviewed on RxList: 1/26/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Virazole Information
- Virazole Drug Interactions Center: ribavirin inhl
- Virazole Side Effects Center
- Virazole Overview including Precautions
- Virazole FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find the secrets to longer life.